Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
Abstract: The present invention relates to a composition for inducing dendritic cell maturation and a method for maturing dendritic cells. More particularly, the present invention relates to a composition including a fusion protein of Rv2299c and ESAT-6, both derived from M. tuberculosis, as an active ingredient for inducing dendritic cell maturation, and a method for differentiating immature dendritic cells into dendritic cells by using the same. The method of the present invention can increase a dendritic cell immune response in the body.
Type:
Grant
Filed:
November 29, 2018
Date of Patent:
August 16, 2022
Assignee:
Quratis Inc.
Inventors:
Hwa-Jung Kim, Han-Gyu Choi, Sung Jae Shin
Abstract: This disclosure provides peptides which bind to LAG3, such as SAPWEPLHWPEDWWQGTGEW (SEQ ID NO:1), and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.
Type:
Grant
Filed:
May 21, 2020
Date of Patent:
August 9, 2022
Assignee:
Leidos, Inc.
Inventors:
Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci, Marc Mansour
Abstract: Multimeric polypeptides and pharmaceutical uses thereof; multimers of alpha3 peptides of an HLA-G antigen and methods of producing such multimers, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. The multimers include at least two monomers, each of said monomers being selected in the group consisting of a peptide P1 of formula X1-X2, wherein X1 represents a peptidic linker including a cysteine amino acid and X2 represents an alpha3 domain of HLA-G.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
August 2, 2022
Assignee:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Inventors:
Joel Le Maoult, Edgardo Delfino Carosella
Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK call cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.
Type:
Grant
Filed:
January 22, 2018
Date of Patent:
June 21, 2022
Assignee:
INNATE PHARMA
Inventors:
Alessandro Moretta, Mariella Della Chiesa
Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of human origin. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided.
Abstract: The disclosure relates generally to methods and compositions of treating or preventing diabetes mellitus by administering to a subject a composition comprising an amount of stem and/or progenitor cells and at least one antigen-specific therapy.
Type:
Grant
Filed:
March 10, 2014
Date of Patent:
May 24, 2022
Assignee:
The Curators of the University of Missouri
Abstract: The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.
Abstract: Embodiments of this invention include methods for detecting in vitro the presence of Memory B cells in peripheral blood mononuclear cells (PBMCs) that produce antibodies reactive to CNS antigens associated with Multiple Sclerosis (MS). Stimulating PBMCs from patients with MS by a polyclonal stimulating agent promotes the ability of B-lymphocytes, when exposed to a CNS antigen, to produce antibodies specific for the CNS antigen. In contrast, stimulating PBMCs from subjects without MS do not produce such responses.
Abstract: This invention discloses the use of Heminth Defense Molecules in methods and compositions for modulating immune responses including treating or preventing undesirable or deleterious immune responses.
Type:
Grant
Filed:
November 1, 2011
Date of Patent:
April 26, 2022
Assignee:
UNIVERSITY OF TECHNOLOGY SYDNEY
Inventors:
Sheila Donnelly, Mark William Robinson, John Pius Dalton, Joyce To
Abstract: The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.
Abstract: Compositions and methods are provided for treating diseases associated with CD100, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CD100 monoclonal antibodies have been developed to neutralize CD100.
Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
March 8, 2022
Assignee:
INNATE PHARMA
Inventors:
Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
Abstract: The invention provides methods of diagnosing and treating multiple sclerosis (MS) patients, including methods of identifying and treating multiple sclerosis patients who are at increased risk of developing a secondary autoimmune disease following lymphocyte depletion, caused, e.g., by treatment with an anti-CD52 antibody. The increased risk may be linked to certain single nucleotide polymorphism genotypes that are indicative of elevated IL-21 levels. Also embraced are methods of selecting treatment regimens for MS patients, and reagents useful in the above methods.
Type:
Grant
Filed:
February 25, 2020
Date of Patent:
February 8, 2022
Assignee:
Cambridge Enterprise Limited
Inventors:
Alasdair J. Coles, Joanne L. Jones, Alastair Compston
Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
January 25, 2022
Assignee:
HiberCell, Inc.
Inventors:
William J. Grossman, Mary A. Antonysamy, Richard M. Walsh, Mariana I. Nelson, Nandita Bose, Michael E. Danielson, Kyle S. Michel
Abstract: The specification describes the sequences for antibodies that recognize the HLA-A2-restricted peptide PR-1 in the context of HLA presentation on the surface of cancer cells. Use of these antibodies in the diagnosis and treatment of cancer and immune-related diseases are also provided.
Type:
Grant
Filed:
February 13, 2018
Date of Patent:
December 7, 2021
Assignee:
Board of Regents, The University of Texas System
Abstract: The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
Type:
Grant
Filed:
January 11, 2018
Date of Patent:
November 23, 2021
Assignee:
Immunomedics, Inc.
Inventors:
David M. Goldenberg, William A. Wegener
Abstract: The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and transforming growth factor beta, (TGF-?).
Type:
Grant
Filed:
June 2, 2020
Date of Patent:
November 16, 2021
Assignee:
Enzo Biochem, Inc.
Inventors:
Robert Nussenblatt, Baoying Liu, Lai Wei, Elazar Rabbani, James J. Donegan